Hola,
Are you new here?

Immuno-Predictor

financed

Mechanical Biomarkers for Prediction of Cancer Immunotherapy

Immunotherapy has revolutionized the treatment of multiple cancers and has already become a standard of care for some tumor types. However, a majority of patients do not benefit from current immunotherapeutics and many develop sev... see more

31/03/2025

UCY

2M€

Project Budget: 2M€

Project leader

UNIVERSITY OF CYPRUS No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

PARTICIPATION DEPralty Sin fecha límite de participación.

Ver 2 Participantes

Financing granted El organismo H2020 notifico la concesión del proyecto The day 2025-03-31

ERC-2019-COG: ERC Consolidator Grant Scope:Objectives

I+D

Cerrada does 6 years

0% 100% 100%

characteristics of the participant

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Private Information

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

UCY

2.00M€ | Leader

LM MACHINES

215.80K€ | participant

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Project duration: 60 months Date Start: 2020-03-16
End date: 2025-03-31

Project leader

UNIVERSITY OF CYPRUS No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Project Budget 2M€

participation deadline Sin fecha límite de participación.

Project description Immunotherapy has revolutionized the treatment of multiple cancers and has already become a standard of care for some tumor types. However, a majority of patients do not benefit from current immunotherapeutics and many develop severe toxicities. Therefore, the identification of biomarkers to classify patients as likely responders or nonresponders to immunotherapy is a timely and of tremendous impact task. My hypothesis is that biomechanical aspects of the tumor microenvironment mediate resistance to immunotherapy. Specifically, many tumors stiffen as they grow and also, tumor growth within the host tissue generates mechanical forces, termed solid stress. Tumor stiffening and solid stress are distinct mechanical abnormalities that compress intratumoral blood vessels, causing hypo-perfusion and hypoxia. Systemic administration of immunotherapeutics requires a well-perfused vasculature, whereas hypo-perfusion and hypoxia promote immunosuppression, helping cancer cells to evade immune responses. The objective of the proposed research is the identification of novel Mechanical Biomarkers related to tumor stiffness, solid stress, perfusion and hypoxia for prediction of immunotherapy. Tumor-bearing mice will be developed and treated with immunotherapeutic drugs and clinically used methods will be combined with computational biomechanical modeling for measuring the Mechanical Biomarkers, making the research transferable to the clinic. The biomarkers will be benchmarked against tumor normalization strategies aiming to restore/normalize mechanical abnormalities and optimize immunotherapy. Finally, the clinical utility of the selected biomarkers will be evaluated in human tumors. Only few tumor-specific biomarkers are used in the clinic - based mainly on genomic analysis. This project is expected to lead to the first biomarkers for immunotherapy prediction exploiting tumor mechanics.

Conecta tu I+D

Entra hoy

Forgot your password?

Financing

Companies

CTIs/Universidades

Projects

researchers